atorvastatin + CKD-519

Atorvastatin + CKD-519 is a combination of two lipid-lowering agents. Atorvastatin is a widely used statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to reduced low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk. It may also have renoprotective effects in patients with chronic kidney disease (CKD), though evidence for slowing eGFR decline is mixed[1][5]. CKD-519 is a potent and selective cholesteryl ester transfer protein (CETP) inhibitor developed by Chong Kun Dang Pharmaceutical for the treatment of dyslipidemia; it raises high-density lipoprotein cholesterol (HDL-C) by inhibiting CETP-mediated transfer of cholesteryl esters between lipoproteins[6]. The combination targets both LDL-C reduction and HDL-C elevation, potentially offering complementary benefits in managing dyslipidemia and reducing cardiovascular risk.

Brand names

Lipitor

Other names

atorvastatin calcium